| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Humanized (from mouse) |
| Target | Dabigatran |
| Clinical data | |
| Trade names | Praxbind |
| Other names | BI-655075 |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Pregnancy category |
|
| Routes of administration |
Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C2131H3299N555O671S11 |
| Molar mass | 47782.71 g·mol−1 |
Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran.
Idarucizumab was developed by Boehringer Ingelheim. One study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation caused by dabigatran within minutes.
It was approved for medical use in the United States and in the European Union in 2015.
Society and culture
Names
Idarucizumab is the International nonproprietary name (INN). The description was updated in 2016. Idarucizumab is the United States Adopted Name (USAN).
See also
External links
- "Idarucizumab". Drug Information Portal. U.S. National Library of Medicine.